ERS Virtual Research Seminar

Unravelling Severe Exacerbations of COPD.
Collaboration in COPD Exacerbations (CICERO);
an ERS Clinical Research Collaboration

25 June 2021, Online

09:00 – 09:10 Welcome and introduction - Neil Greening (UK) and Kristina Vermeersch (BE)

Session 1  Characterisation and features of severe exacerbations of COPD
Chairs: Chin Kook Rhee (KR) and Huib Kerstjens (NL)

09:10 – 09:25 How can treatable traits be used in severe exacerbations? – Mona Bafadhel, UK
09:25 – 09:40 Are severe and moderate exacerbations different entities? – Timm Greulich, DE
09:40 – 09:55 How can real-world data be used to improve outcomes? – Jennifer Quint, UK
09:55 – 10:15 Discussion

10:15 – 10:25 Break

Session 2  Addressing the non-pulmonary features of hospitalization for exacerbations of COPD
Chairs: Chin Kook Rhee (KR) and Huib Kerstjens (NL)

10:25 – 10:40 Cardiac dysfunction – Marco Contoli, IT
10:40 – 10:55 Sarcopenia and muscle dysfunction – Neil Greening, UK
10:55 – 11:10 Palliation and end-of-life care – Daisy Janssen, NL
11:10 – 11:30 Discussion

11:30 – 11:40 Break

Session 3  Treatments at preventing readmission to hospital for COPD
Chairs: Therese Lapperre (BE) and Nicola Scichilone (IT)

11:40 – 11:55 Pharmacological treatments – Wim Janssens, BE
11:55 – 12:10 Ventilation strategies during and after discharge from hospital – Lara Pisani, IT
12:10 – 12:25 Rehabilitation strategies around the time of hospitalisation – Sally Singh, UK
12:25 – 12:45 Discussion

12:45 – 13:30 Lunch break

All timings are in Central European Time (CET)
Session 4  Breakout session

13:30 – 15:00  **Group 1:** Phenotyping exacerbations for inflammation, the microbiome, and response. What are the key targets?
Chair: Mona Bafadhel

Questions that will be answered:
1. What are the known inflammatory phenotypes of COPD?
2. What is known about the eosinophilic, neutrophilic phenotype? Causes, presentation
3. Are OCS suitable for everyone?
4. Are antibiotics suitable for everyone?
5. What other treatments are available? What is missing?
6. What techniques are best for characterising the microbiome?
7. What does OCS do to the airway microbiome?

**Group 2:** What are the key interventions and outcome measure for severe exacerbations of COPD?
Chair: Wim Janssens

Questions that will be answered:
1. Which outcomes are the most relevant of acute hospitalized exacerbations?
2. Do we need more sensitive prognostic scores during and after hospital admission?
3. How long do we consider outcomes being determined by the index event?
4. What type of interventions need priority for studying in the acute situation?
5. Do we need home based monitoring post discharge?

15:00 – 15:40  Round table discussion of breakout sessions (20min per group)
Chairs: Mona Bafadhel (UK) and Wim Janssens (BE)

15:40 – 15:55  Break

Session 5  New horizons for severe exacerbations of COPD
Chairs: Therese Lapperre (BE) and Nicola Scichilone (IT)

15:55 – 16:10  What new biomarkers are on the horizon for severe exacerbations? – Pierre-Régis Burgel, FR
16:10 – 16:25  What data should be collected during severe exacerbations? – Frits Franssen, NL
16:25 – 16:45  Discussion

16:45 – 16:55  Break

Session 6  Next steps for Severe Exacerbations of COPD and CICERO
Chairs: Neil Greening (UK) and Kristina Vermeersch (BE)

16:55 – 17:40  Facilitated discussion on outcomes of seminar and overview of CATALINA study – Neil Greening and Kristina Vermeersch
17:40 – 18:00  Remarks, wrap-up and action points – Mona Bafadhel and Wim Janssens

*All timings are in Central European Time (CET)*